EXHIBIT 99.1

ROCKWELL
--------------------------------------------------------------------------------
+MEDICAL TECHNOLOGIES, INC.

COMPANY PRESS RELEASE                       Contact: Thomas Klema (248) 960-9009

ROCKWELL MEDICAL TECHNOLOGIES, INC. COMMENCES WARRANT EXCHANGE OFFER

WIXOM, MICHIGAN, October 20, 2005 - Rockwell Medical Technologies, Inc.
(Nasdaq:RMTI), a dialysis products manufacturer serving the healthcare industry,
reported today that the U.S. Securities and Exchange Commission (SEC) has
declared effective Rockwell's registration statement relating to its warrant
exchange offer.

Under the terms of the exchange offer, each of Rockwell's current outstanding
publicly traded common share purchase warrants (Nasdaq: RMTIW) with an exercise
price of $4.50 can be exchanged for a new common share purchase warrant with an
exercise price of $3.90. The exchange offer expires at 5:00 pm (EST), November
28, 2005. Both old and new warrants will expire on January 26, 2006. Rockwell
currently has 3,625,000 outstanding publicly traded common share purchase
warrants.

Rockwell expects it could raise more than $13,800,000 if all the old warrants
are exchanged for new warrants and subsequently all of the new warrants are
exercised by the warrant holders. Rockwell intends to use a portion of the
proceeds raised from the warrant exercise for business expansion including
additional production facilities, and intends to utilize the majority of the
proceeds to obtain FDA approval for its proprietary iron-delivery product. As
demonstrated during Phase II clinical trials, and compared to the current IV
iron delivery method, Rockwell's iron-delivery product provides a safer, more
effective and less costly delivery of iron to the dialysis patient. Iron
supplementation is vital to achieve adequate therapeutic response to expensive
anemia treatments received by 90% of all dialysis patients. Upon FDA approval,
Rockwell expects its proprietary iron-delivery product to aggressively compete
in the $300,000,000 U.S. iron market as well as the $500,000,000-plus global
iron market.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We are
at an important stage in the development of our proprietary iron-delivery
product and the capital raised from this exchange offer will be used primarily
to accelerate that initiative and gain FDA market approval. We have separate
studies that we anticipate will begin in the both the fourth quarter of this
year and the first quarter of 2006 and we will keep our shareholders apprised of
our progress." Mr. Chioini further stated, "We are operating in a changing,
dynamic marketplace and we will use our resources to capitalize on
opportunities, including growing our core concentrate business as well as
entering markets such as our iron drug-delivery product."

The terms of the exchange offer are set forth in a prospectus to be provided to
current warrant holders and can be accessed via the internet at:
http://www.sec.gov/Archives/edgar/data/1041024/000095012405005787/0000950124-05-
005787.txt

Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing,
marketing and delivering high-quality dialysis solutions, powders and ancillary
products that improve the quality of care for dialysis patients. Dialysis is a
process that duplicates kidney function for those patients whose kidneys have
failed to work properly and suffer from chronic kidney failure, a condition also
known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis
patients in the United States and the incidence of ESRD has experienced an
average annual increase of approximately 6%-8% over the last decade. Rockwell's
products are used to cleanse the ESRD patient's blood and replace nutrients in
the bloodstream. Rockwell offers the proprietary Dri-Sate(R) Dry Acid
Concentrate Mixing System, RenalPure(R) Liquid Acid Concentrate, SteriLyte(R)
Liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate,
Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.
Rockwell is currently in the process of developing and gaining FDA approval of a
proprietary iron-delivery product which will be administered to dialysis
patients via dialysate. Visit Rockwell's website at www.rockwellmed.com for more
information.

Certain statements in this press release with respect to Rockwell's anticipated
sales revenue or possible proceeds from financing constitute "forward-looking
statements". These statements include statements regarding the amount of
expected proceeds from the exercise of warrants, the use of those proceeds and
the performance of Rockwell's iron-delivery product. These forward-looking
statements reflect management's expectations and are based upon currently
available information. Management of Rockwell believes the expectations
reflected in the forward-looking statements made in this press release are based
upon reasonable assumptions. However, certain factors could occur that might
cause actual results to vary. These include, but are not limited to, general
economic conditions, economic conditions in the hemodialysis industry,
competitive factors and other factors discussed in Rockwell's reports filed with
the Securities and Exchange Commission. The forward-looking statements should be
considered in light of these risks and uncertainties.